Figure 5
The concentration vs. time curves for sorafenib in the plasma of rats treated under different time schedules with or without irradiation (RT) in (I) the sorafenib only (40 mg/kg, orally (p.o.)) group and (II) the cyclosporine A (CsA, a P-glycoprotein [P-gp] inhibitor, 20 mg/kg, i.p. 30 min before RT) pretreatment group. (A) For whole-liver RT at 2 Gy (RT2Gy) in group I: (a) sham RT + sorafenib (40 mg/kg) (●); (b) RT2Gy + sorafenib (40 mg/kg, p.o.) 1 hr later (○); (c) RT2Gy + sorafenib (40 mg/kg, p.o.) 24 hr later (▼). For whole-liver RT2Gy in group II: (a) CsA (20 mg/kg, i.p.) + sorafenib (40 mg/kg, p.o.) (∆); (b) CsA (20 mg/kg, i.p.) + RT2Gy + sorafenib (40 mg/kg, p.o.) 1 hr later (■); (c) CsA (20 mg/kg, i.p.) + RT2Gy + sorafenib (40 mg/kg, p.o.) 24 hr later (□). (B) For 1.5 × 1.5 cm RT at 9 Gy (RT9Gy) in group I: (a) sham RT + sorafenib (40 mg/kg (●); (b) RT9Gy + sorafenib (40 mg/kg, p.o.) 1 hr later (○); (c) RT9Gy + sorafenib (40 mg/kg, p.o.) 24 hr later (▼). For 1.5 × 1.5 cm RT9Gy in group II: (a) CsA (20 mg/kg, i.p.) + sorafenib (40 mg/kg, p.o.) (∆); (b) CsA (20 mg/kg, i.p.) + RT9Gy + sorafenib (40 mg/kg, p.o.) 1 hr later (■); (c) CsA (20 mg/kg, i.p.) + RT9Gy + sorafenib (40 mg/kg, p.o.) 24 hr later (□). The data are expressed as the mean ± SEM values (n = 6 per group).
